{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:34:22Z","timestamp":1792427662906,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Familial hypercholesterolemia (FH) is a genetic condition characterized by elevated LDL-C and increased cardiovascular risk. Beyond LDL-C levels, the impact of genotype on glucose homeostasis has not been well evaluated. We aimed to evaluate the impact of genotype on glycemic status and on atherosclerotic injury in FH subjects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a cross-sectional study on 322 FH subjects not on lipid-lowering therapy and without history of cardiovascular disease. Biochemical and genetic analyses as well as vascular profile assessment were obtained from all subjects. The study population was divided into two groups according to genotype: LDL receptor (LDLR) group and non-LDLR (NLDLR) group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The LDLR group exhibited a higher prevalence of low glycemic status (LGS) than the NLDLR group (44.1% vs. 26%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), whereas a high glycemic status (HGS) was more prevalent in the NLDLR group compared with LDLR group (74% vs. 55.9%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). The NLDLR group exhibited a higher prevalence of peripheral atherosclerotic plaques than the LDLR group (93.4% vs. 73%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), while coronary artery calcification (CAC) presence was more prevalent in the LDLR group compared with the NLDLR group (74.7% vs. 48%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). In a secondary analysis the study population was stratified into three groups based on LDLR genotype: NLDLR, LDLR defective, LDLR null groups. The prevalence of LGS progressively increased from the NLDLR to the LDLR null group, while HGS showed an inverse trend (<jats:italic>p<\/jats:italic> for trend\u2009&lt;\u20090.05). Peripheral atherosclerotic plaque prevalence decreased from the NLDLR to the LDLR null group (<jats:italic>p<\/jats:italic> for trend\u2009&lt;\u20090.05), while CAC prevalence increased progressively in the three groups (<jats:italic>p<\/jats:italic> for trend\u2009&lt;\u20090.01). Logistic regression analysis showed that FH groups with an LDLR mutation were inversely associated with HGS (<jats:italic>p<\/jats:italic> for both\u2009&lt;\u20090.01) and the LDLR null group exhibited the strongest association.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>FH subjects with NLDLR mutations exhibited a worse glycemic profile, while null LDLR mutations showed the strongest inverse association with HGS. The integrations of genetic, lipid and glucose data could be useful to better identify the metabolic profile and the atherosclerosis distribution in FH subjects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Research insights<\/jats:title>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>What is currently known about this topic?<\/jats:title>\n            <jats:p>Familial hypercholesterolemia (FH) is characterized by elevated LDL-C levels. LDLR null mutations protected pancreatic \u03b2-cells from cholesterol accumulation. NGS has improved FH diagnosis by analysis of all genes implicated in the lipid disorder.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>What is the key research question?<\/jats:title>\n            <jats:p>What is the impact of FH genotype (monogenic with or without LDLR mutation\/polygenic) on glycemic status?<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>What is new?<\/jats:title>\n            <jats:p>FH population was characterized by a heterogeneous glycemic profile according to LDLR mutation. LDL-C and plasma glucose could modulate the distribution of subclinical atherosclerosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>How might this studyinfluence clinical practice?<\/jats:title>\n            <jats:p>Genetic, lipid, glucose data could better identify the metabolic and atherosclerotic profiles in FH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12933-025-02683-y","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T15:46:12Z","timestamp":1742485572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation"],"prefix":"10.1186","volume":"24","author":[{"given":"Francesco","family":"Di Giacomo Barbagallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giosiana","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Scilletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Miano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Musmeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Marted\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gonz\u00e1lez-Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Ibarretxe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernestina Marianna","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Malaguarnera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Masana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Scicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2683_CR1","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","volume":"4","author":"RD Santos","year":"2016","unstructured":"Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016;4:850\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2683_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.numecd.2017.07.003","volume":"28","author":"R Scicali","year":"2018","unstructured":"Scicali R, Di Pino A, Platania R, Purrazzo G, Ferrara V, Giannone A, et al. Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: clinical, genetic and atherosclerotic burden profile. Nutr Metabol Cardiovasc Dis. 2018;28:35\u201343.","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"2683_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/HCO.0000000000000385","volume":"30","author":"CS Bruikman","year":"2017","unstructured":"Bruikman CS, Hovingh GK, Kastelein JJP. Molecular basis of familial hypercholesterolemia. Curr Opin Cardiol. 2017;30:262\u20136.","journal-title":"Curr Opin Cardiol"},{"key":"2683_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosissup.2017.07.001","volume":"29","author":"M Averna","year":"2017","unstructured":"Averna M, Cefal\u00f9 AB, Casula M, Noto D, Arca M, Bertolini S, et al. Familial hypercholesterolemia: the Italian Atherosclerosis Society Network (LIPIGEN). Atheroscler Suppl. 2017;29:11\u20136.","journal-title":"Atheroscler Suppl"},{"key":"2683_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA J Am Med Assoc. 2016;316:1383\u201391.","journal-title":"JAMA J Am Med Assoc"},{"key":"2683_CR6","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1210\/en.2002-220273","volume":"143","author":"M Cnop","year":"2002","unstructured":"Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet \u03b2-cells by its cellular uptake and oxidative modification. Endocrinology. 2002;143:3449\u201353.","journal-title":"Endocrinology"},{"key":"2683_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12192-011-0265-7","volume":"16","author":"X Lu","year":"2011","unstructured":"Lu X, Liu J, Hou F, Liu Z, Cao X, Seo H, et al. Cholesterol induces pancreatic \u03b2 cell apoptosis through oxidative stress pathway. Cell Stress Chaperones. 2011;16:539\u201348.","journal-title":"Cell Stress Chaperones"},{"key":"2683_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/nu14071503","volume":"14","author":"AM Gonz\u00e1lez-Lle\u00f3","year":"2022","unstructured":"Gonz\u00e1lez-Lle\u00f3 AM, S\u00e1nchez-Hern\u00e1ndez RM, Boronat M, W\u00e4gner AM. Diabetes and familial hypercholesterolemia: interplay between lipid and glucose metabolism. Nutrients. 2022;14:1503.","journal-title":"Nutrients"},{"key":"2683_CR9","doi-asserted-by":"publisher","first-page":"100676","DOI":"10.1016\/j.ajpc.2024.100676","volume":"18","author":"DA Scott","year":"2024","unstructured":"Scott DA, Ponir C, Shapiro MD, Chevli PA. Associations between insulin resistance indices and subclinical atherosclerosis: a contemporary review. Am J Prev Cardiol. 2024;18:100676.","journal-title":"Am J Prev Cardiol"},{"key":"2683_CR10","doi-asserted-by":"publisher","first-page":"e3367","DOI":"10.1002\/dmrr.3367","volume":"37","author":"R Scicali","year":"2021","unstructured":"Scicali R, Giral P, D\u2019Erasmo L, Cluzel P, Redheuil A, Di Pino A, et al. High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. Diabetes Metab Res Rev. 2021;37:e3367.","journal-title":"Diabetes Metab Res Rev"},{"key":"2683_CR11","doi-asserted-by":"publisher","first-page":"a2423","DOI":"10.1136\/bmj.a2423","volume":"337","author":"J Versmissen","year":"2008","unstructured":"Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.","journal-title":"BMJ"},{"key":"2683_CR12","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J [Internet]. 2015;36:2425\u201337.","journal-title":"Eur Heart J [Internet]."},{"key":"2683_CR13","doi-asserted-by":"publisher","first-page":"11863","DOI":"10.1038\/s41598-017-11070-x","volume":"7","author":"F Urbano","year":"2017","unstructured":"Urbano F, Bugliani M, Filippello A, Scamporrino A, Di Mauro S, Di Pino A, et al. Atorvastatin but not pravastatin impairs mitochondrial function in human pancreatic islets and rat \u03b2-cells. Direct effect of oxidative stress. Sci Rep. 2017;7:11863.","journal-title":"Sci Rep"},{"key":"2683_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1530\/EJE-19-0173","volume":"181","author":"F Urbano","year":"2019","unstructured":"Urbano F, Di Pino A, Scicali R, Filippello A, Di Mauro S, Scamporrino A, et al. Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy. Eur J Endocrinol. 2019;181:579\u201390.","journal-title":"Eur J Endocrinol"},{"key":"2683_CR15","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1194\/jlr.D079301","volume":"58","author":"MA Iacocca","year":"2017","unstructured":"Iacocca MA, Wang J, Dron JS, Robinson JF, McIntyre AD, Cao H, et al. Use of next-generation sequencing to detect LDLR gene copy number variation in familial hypercholesterolemia. J Lipid Res. 2017;58:2202\u20139.","journal-title":"J Lipid Res"},{"key":"2683_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.atherosclerosis.2018.08.013","volume":"277","author":"M Casula","year":"2018","unstructured":"Casula M, Olmastroni E, Pirillo A, Catapano AL, Arca M, Averna M, et al. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: the LIPIGEN study. Atherosclerosis. 2018;277:413\u20138.","journal-title":"Atherosclerosis"},{"key":"2683_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.atherosclerosis.2011.08.004","volume":"219","author":"H Tada","year":"2011","unstructured":"Tada H, Kawashiri M, Ohtani R, Noguchi T, Nakanishi C, Konno T, et al. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis. 2011;219:663\u20136.","journal-title":"Atherosclerosis"},{"key":"2683_CR18","doi-asserted-by":"publisher","first-page":"e023668","DOI":"10.1161\/JAHA.121.023668","volume":"11","author":"E Olmastroni","year":"2022","unstructured":"Olmastroni E, Gazzotti M, Arca M, Averna M, Pirillo A, Catapano AL, et al. Twelve variants polygenic score for low-density lipoprotein cholesterol distribution in a large cohort of patients with clinically diagnosed familial hypercholesterolemia with or without causative mutations. J Am Heart Assoc. 2022;11:e023668.","journal-title":"J Am Heart Assoc"},{"key":"2683_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jcmg.2012.03.013","volume":"5","author":"H Sillesen","year":"2012","unstructured":"Sillesen H, Muntendam P, Adourian A, Entrekin R, Garcia M, Falk E, et al. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the high risk plaque bioimage study. JACC Cardiovasc Imaging. 2012;5:681\u20139.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2683_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejim.2024.12.002","volume":"132","author":"G Bosco","year":"2024","unstructured":"Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Capuccio S, et al. Evaluations of metabolic and innate immunity profiles in subjects with familial hypercholesterolemia with or without subclinical atherosclerosis. Eur J Intern Med [Internet]. 2024;132:118\u201326.","journal-title":"Eur J Intern Med [Internet]."},{"key":"2683_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijcard.2017.01.001","volume":"231","author":"S Basili","year":"2017","unstructured":"Basili S, Loffredo L, Pastori D, Proieti M, Farcomeni A, Vesti AR, et al. Carotid plaque detection improves the predictve value of CHA2DS2-VASc score in patients with non-valvular atrial fibrilation: the ARAPACIS Study. Int J Cardiol. 2017;231:143\u20139.","journal-title":"Int J Cardiol"},{"key":"2683_CR22","doi-asserted-by":"publisher","first-page":"1346152","DOI":"10.3389\/fendo.2024.1346152","volume":"15","author":"G Bosco","year":"2024","unstructured":"Bosco G, Di Giacomo BF, Di Marco M, Miano N, Scilletta S, Spampinato S, et al. The impact of SLCO1B1 rs4149056 on LDL-C target achievement after lipid lowering therapy optimization in men and women with familial hypercholesterolemia. Front Endocrinol (Lausanne). 2024;15:1346152.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2683_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12933-023-02065-2","volume":"22","author":"M Di Marco","year":"2023","unstructured":"Di Marco M, Scilletta S, Miano N, Marrano N, Natalicchio A, Giorgino F, et al. Cardiovascular risk and renal injury profile in subjects with type 2 diabetes and non-albuminuric diabetic kidney disease. Cardiovasc Diabetol. 2023;22:344.","journal-title":"Cardiovasc Diabetol"},{"key":"2683_CR24","doi-asserted-by":"crossref","unstructured":"Draznin B, Aroda R. V, Bakris G, Benson G, Brown M. F, Freeman R, et al. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142022. American Diabetes Association Professional Practice Committee. Diabetes Care. 2022;45.","DOI":"10.2337\/dc22-S002"},{"key":"2683_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000369441","volume":"42","author":"M P\u00f6tschke-Langer","year":"2015","unstructured":"P\u00f6tschke-Langer M, Schotte K, Szilagyi T. The WHO framework convention on tobacco control. Prog Respir Res. 2015;42:149\u201357.","journal-title":"Prog Respir Res"},{"key":"2683_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","volume":"31","author":"R Scicali","year":"2021","unstructured":"Scicali R, Di Pino A, Urbano F, Ferrara V, Marchisello S, Di Mauro S, et al. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. Nutr Metabol Cardiovasc Dis. 2021;31:869\u201379.","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"2683_CR27","doi-asserted-by":"publisher","first-page":"e14083","DOI":"10.1111\/eci.14083","volume":"54","author":"R Scicali","year":"2024","unstructured":"Scicali R, Bosco G, Scamporrino A, Di Mauro S, Filippello A, Di Giacomo Barbagallo F, et al. Evaluation of high-density lipoprotein-bound long non-coding RNAs in subjects with familial hypercholesterolaemia. Eur J Clin Invest. 2024;54:e14083.","journal-title":"Eur J Clin Invest"},{"key":"2683_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00592-021-01703-z","volume":"58","author":"R Scicali","year":"2021","unstructured":"Scicali R, Di Pino A, Ferrara V, Rabuazzo AM, Purrello F, Piro S. Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting. Acta Diabetol. 2021;58:949\u201357.","journal-title":"Acta Diabetol"},{"key":"2683_CR29","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1161\/CIRCULATIONAHA.120.049057","volume":"142","author":"R Mszar","year":"2020","unstructured":"Mszar R, Nasir K, Santos RD. Coronary artery calcification in familial hypercholesterolemia. Circulation. 2020;142:1405\u20137.","journal-title":"Circulation"},{"key":"2683_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.atherosclerosis.2013.10.004","volume":"231","author":"D Rosenbaum","year":"2013","unstructured":"Rosenbaum D, Giral P, Chapman J, Rached FH, Kahn JF, Bruckert E, et al. Radial augmentation index is a surrogate marker of atherosclerotic burden in a primary prevention cohort. Atherosclerosis. 2013;231:436\u201341.","journal-title":"Atherosclerosis"},{"key":"2683_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jacl.2018.09.008","volume":"13","author":"M Paquette","year":"2019","unstructured":"Paquette M, Bernard S, Ruel I, Blank DW, Genest J, Baass A. Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia. J Clin Lipidol. 2019;13:123\u20138.","journal-title":"J Clin Lipidol"},{"key":"2683_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","volume":"40","author":"L Da Dalt","year":"2019","unstructured":"Da Dalt L, Ruscica M, Bonacina F, Balzarotti G, Dhyani A, Di Cairano E, et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J. 2019;40:357\u201368.","journal-title":"Eur Heart J"},{"key":"2683_CR33","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.bbadis.2019.04.012","volume":"1865","author":"C Perego","year":"2019","unstructured":"Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, Norata GD. Cholesterol metabolism, pancreatic \u03b2-cell function and diabetes. Biochim Biophys Acta Mol Basis Dis. 2019;1865:2149\u2013456.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2683_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10528-017-9827-4","volume":"56","author":"M Szabo","year":"2018","unstructured":"Szabo M, M\u00e1t\u00e9 B, Cs\u00e9p K, Benedek T. Genetic approaches to the study of gene variants and their impact on the pathophysiology of type 2 diabetes. Biochem Genet. 2018;56:22\u201355.","journal-title":"Biochem Genet"},{"key":"2683_CR35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jama.2015.1206","volume":"313","author":"J Besseling","year":"2015","unstructured":"Besseling J, Kastelein JJP, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA J Am Med Assoc. 2015;313:1029\u201336.","journal-title":"JAMA J Am Med Assoc"},{"key":"2683_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/clinchem\/hvaa275","volume":"67","author":"P Libby","year":"2021","unstructured":"Libby P. Inflammation in atherosclerosis\u2014no longer a theory. Clin Chem. 2021;67:131\u201342.","journal-title":"Clin Chem"},{"key":"2683_CR37","doi-asserted-by":"publisher","first-page":"152786","DOI":"10.1155\/2013\/152786","volume":"2013","author":"A Pirillo","year":"2013","unstructured":"Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786.","journal-title":"Mediators Inflamm"},{"key":"2683_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","volume":"88","author":"RA DeFronzo","year":"2004","unstructured":"DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin N Am. 2004;88:787\u2013835.","journal-title":"Med Clin N Am"},{"key":"2683_CR39","doi-asserted-by":"publisher","first-page":"3634948","DOI":"10.1155\/2016\/3634948","volume":"2016","author":"A Janus","year":"2016","unstructured":"Janus A, Szahidewicz-Krupska E, Mazur G, Doroszko A. Insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders. Mediators Inflamm. 2016;2016:3634948.","journal-title":"Mediators Inflamm"},{"key":"2683_CR40","first-page":"918267","volume":"2012","author":"GK Kolluru","year":"2012","unstructured":"Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: Effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012;2012:918267.","journal-title":"Int J Vasc Med."},{"key":"2683_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/ATVBAHA.123.319957","volume":"44","author":"M Paquette","year":"2024","unstructured":"Paquette M, Cariou B, Bernard S, Hegele RA, Gallo A, Genest J, et al. Increased FH-risk-score and diabetes are cardiovascular risk equivalents in heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2024;44:505\u201312.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2683_CR42","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41371-019-0273-0","volume":"33","author":"A Aboonabi","year":"2019","unstructured":"Aboonabi A, Meyer RR, Singh I. The association between metabolic syndrome components and the development of atherosclerosis. J Hum Hypertens. 2019;33:844\u201355.","journal-title":"J Hum Hypertens"},{"key":"2683_CR43","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","volume":"128","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128:1728\u201346.","journal-title":"Circ Res"},{"key":"2683_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41577-021-00584-1","volume":"22","author":"P Roy","year":"2022","unstructured":"Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22:251\u201365.","journal-title":"Nat Rev Immunol"},{"key":"2683_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lanepe.2024.101182","volume":"49","author":"Y Chen","year":"2025","unstructured":"Chen Y, Zhong Z, Gue Y, Banach M, McDowell G, Mikhailidis DP, et al. Impact of surrogates for insulin resistance on mortality and life expectancy in primary care: a nationwide cross-sectional study with registry linkage (LIPIDOGRAM2015). Lancet Regional Health Europe. 2025;49:1\u201315.","journal-title":"Lancet Regional Health Europe"},{"key":"2683_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12933-023-01819-2","volume":"22","author":"F Liu","year":"2023","unstructured":"Liu F, Ling Q, Xie S, Xu Y, Liu M, Hu Q, et al. Association between triglyceride glucose index and arterial stiffness and coronary artery calcification: a systematic review and exposure-effect meta-analysis. Cardiovasc Diabetol. 2023;22:111.","journal-title":"Cardiovasc Diabetol"},{"key":"2683_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01268-9","volume":"20","author":"X Ding","year":"2021","unstructured":"Ding X, Wang X, Wu J, Zhang M, Cui M. Triglyceride\u2013glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol. 2021;20:1\u201313.","journal-title":"Cardiovasc Diabetol"},{"key":"2683_CR48","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.atherosclerosis.2012.02.043","volume":"222","author":"P Caballero","year":"2012","unstructured":"Caballero P, Alonso R, Rosado P, Mata N, Fern\u00e1ndez-Friera L, Jim\u00e9nez-Borreguero LJ, et al. Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities. Atherosclerosis. 2012;222:468\u201372.","journal-title":"Atherosclerosis"},{"key":"2683_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.athplu.2022.10.002","volume":"50","author":"S Borg","year":"2022","unstructured":"Borg S, S\u00f8rensen Bork C, Skjelbo Nielsen MR, J\u00f3anesarson J, Zaremba T, Lolas IBY, et al. Subclinical atherosclerosis determined by coronary artery calcium deposition in patients with clinical familial hypercholesterolemia. Atheroscler Plus. 2022;50:65\u201371.","journal-title":"Atheroscler Plus"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02683-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T15:32:31Z","timestamp":1742571151000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02683-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2683"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02683-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (Comitato Etico Catania 2, Piazza Santa Maria di Ges\u00f9 n\u00b0 5, Catania, Italy, protocol n. 19\/C.E. 10 November 2015). The participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}